The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
about
DangER: protein ovERload. Targeting protein degradation to treat myelomaAutophagy in plasma cell pathophysiologyKRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.Trial Watch: Proteasomal inhibitors for anticancer therapyMolecular mechanisms of bortezomib resistant adenocarcinoma cellsCombined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupMolecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Cadmium induced p53-dependent activation of stress signaling, accumulation of ubiquitinated proteins, and apoptosis in mouse embryonic fibroblast cells.Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Development of inhibitors in the ubiquitination cascade.Proteasome dysfunction mediates high glucose-induced apoptosis in rodent beta cells and human isletsBortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsProtein folding and quality control in the endoplasmic reticulum: Recent lessons from yeast and mammalian cell systems.GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.Quantitative analysis of a ubiquitin-dependent substrate using capillary electrophoresis with dual laser-induced fluorescence.PiZ mouse liver accumulates polyubiquitin conjugates that associate with catalytically active 26S proteasomesAntimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesisA plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cellsThe novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaThe 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Iron increases the susceptibility of multiple myeloma cells to bortezomib.TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Endoplasmic reticulum stress: its role in disease and novel prospects for therapy.The immunoproteasome as a target in hematologic malignancies.Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.Kidney disease associated with plasma cell dyscrasiasClinical and investigational use of proteasome inhibitors for transplant rejection.Proteasome inhibitors: an expanding army attacking a unique target.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Light chain amyloidosis 2012: a new era.Proteasome inhibitors in acute leukemia.
P2860
Q26825417-B974E96C-8DFC-4978-9437-650D86CE67BEQ27015920-BCB6C0C0-7FBC-49FB-8F97-932445B5DFCEQ27853300-B15E6B1E-6058-4FCE-BAD8-556C135511E7Q28082910-842ABD3D-0339-43F0-86B3-36E36D9271CBQ28478538-5939C4A5-CC21-40AC-8BCF-8315AABA7E71Q34372977-350A8AD7-2086-4904-A077-5D86D5578A47Q34542087-BFDD1EE3-6109-4296-99A7-98836D518BC1Q34585047-21235131-F231-44D0-9F31-EEBB5A8499AFQ34608271-7B993FD8-B180-4802-8C52-F971DE0E1138Q34701812-FF0480BD-E78C-4534-868B-431268F9BD0CQ34999190-430D6885-A6FF-42CF-9911-3695853B51E7Q35024457-98EB5560-3C9D-4D92-B903-EDE5C4159268Q35044801-12CD762B-6549-4D1D-BB7E-4043B5F99240Q35123951-721B46D4-31F0-40EF-A90F-B788BEB54714Q35142790-76FE8631-753D-4075-B54E-BE4A3E3A301DQ35160159-DD13A440-15DE-4F5F-BF5F-C15AA62B408BQ35208033-C1F5D8B1-B6CD-4FF4-9A61-567F56EB9B56Q35214583-0E5E2740-785B-4BFE-9354-0789BC74BEBCQ35247414-787A799F-A0FF-4C14-B010-2F04B7F2AC63Q35251058-B9966428-7EC1-4555-8BBD-9122662AF401Q35997166-B64371AA-FA82-4A75-AD56-269E92798980Q36111590-76CDFB7C-960F-47B7-B2CA-3DC950F495CBQ36115692-AE33E65F-949C-4555-B6B2-85F02F2CB895Q36150369-E4A4259B-7ABE-4E47-A550-BC2119407180Q36226588-7F513E55-D1B6-4B9E-AA0A-885593FDD32CQ36444233-64E7761E-D3E6-4977-8ADF-E63DAF1662CFQ36709283-E69EED85-1934-4EE4-8ABF-82C3DA9454A9Q36892625-F1344F44-743D-4892-9F04-9A2FAD513695Q37007610-94BD8BE3-9C33-42D9-89A4-75E6499CFA1AQ37171812-20327CD3-86AA-45B1-A144-45F5C2163258Q37288073-15901233-B6A6-4C07-A957-37AD478F97EEQ37393379-634E5BA1-78EF-41B5-AC26-9C8FD9B56761Q37673360-F6DF892D-88DB-4CB1-A81F-F8579CB45572Q37750106-A6F79FD7-A28B-4BDB-9FD8-0ECEC434803FQ37931981-4AEB877D-4C79-4585-B225-F802E1B0E5C3Q37979388-0C926CCA-0585-4695-850D-546DC7DE5CFEQ38019864-04E1FEDF-BE61-49E2-8C18-E309748BEE01Q38035044-CAE77B43-97D2-4278-B152-BED65C0C415EQ38072108-6B39785D-ECCE-474B-8AD4-904E7BB6C2FEQ38088003-37F4DA49-C258-428A-AAF4-61CCB82C161A
P2860
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The proteasome load versus cap ...... ells to proteasome inhibition.
@en
The proteasome load versus cap ...... ells to proteasome inhibition.
@nl
type
label
The proteasome load versus cap ...... ells to proteasome inhibition.
@en
The proteasome load versus cap ...... ells to proteasome inhibition.
@nl
prefLabel
The proteasome load versus cap ...... ells to proteasome inhibition.
@en
The proteasome load versus cap ...... ells to proteasome inhibition.
@nl
P2093
P50
P1433
P1476
The proteasome load versus cap ...... cells to proteasome inhibition
@en
P2093
Alexandre Mezghrani
Andrea Orsi
Elena Pasqualetto
Fulvia Cerruti
Giada Bianchi
Laura Oliva
Paolo Cascio
Valeria Calbi
P304
P356
10.1182/BLOOD-2008-08-172734
P407
P50
P577
2009-01-22T00:00:00Z